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EDITORIAL

Nutrition in CKD: Songgaar j Burungaar

T

his issue of Advances in Chronic Kidney Disease provides equipoise regarding dietary therapy in CKD.
The guest editors, Drs. Holly Kramer and Julie Lin,
have patiently plaited together a series of up-to-date reviews regarding the whys and wherefores of nutritional
intervention in patients with nondialysis-dependent
CKD and those with ESRD. Kramer and Lin challenge
you, the reader, to examine current views of medical nutritional therapy issues relevant to kidney patients, with
the overarching mission of undergirding you with greater
knowledge, so that you may take action with timely,
structured decision-making on behalf of CKD patients
with nutritional issues, possibly the area that receives
the least volume of formalized training in nephrology.
The Tuvan word for ‘‘the past’’ and ‘‘go forward’’ is
‘‘burungaar.’’1 The word ‘‘songgaar’’ means ‘‘the future’’
and to ‘‘go back’’. These concepts are opposite to the
Western model of forward-peering to the future and
backward-looking to the past, but using the Tuvan concept of time facilitates our understanding of why we simply do not deliver adequate nutritional content and care
in CKD. To determine the value of medical nutritional
therapy in CKD mandates both.
Excessive dietary protein has long been considered to
facilitate kidney demise in individuals with CKD, by
Beale in 1869 and Smith afterward in 1926, who successfully enforced severe protein restriction (0.26 mg/kg) in
an azotemic patient for 6 months.2 However, therapeutic
nutritional privation and the negative consequences of
protein restriction forced this dietary alternative to fall
into disfavor. In the early to mid-1960s, Giordano, who
advised 2 to 3 g of nitrogen daily, and Giovanetti and
Maggiore, who advocated for a high biological value
protein-restricted diet combined with calorie sufficiency
from wheat starch pasta and cornstarch wafers, demonstrated the possibility of lifesaving nutritional therapy
in advanced CKD patients.3 Later, other kidney nutritional devotees increased the amounts of protein to stave
off the possibility of protein-energy wasting, and protein

intake levels were adjusted to prevent uremic symptoms.
Ketoacid administration was shown later to demonstrate
a salutary, protein-sparing effect, but was minimally
adopted in the United States.4
Protein, phosphorus (calcium-phosphate precipitation
hypothesis), and caloric controls were not simultaneously
implemented in any of these investigations because acceptance of the various toxicities of each were at differing
points in their respective evolutions of acknowledgement. Therefore, definitive conclusions could not be
drawn from many of them. Intact animals with normal
kidneys developed kidney hypertrophy with high dietary
protein loads. In animals with prior glomerular injury
or near-total kidney ablation (5/6 nephrectomy), glomerulosclerosis occurred in the face of relatively excessive
protein intake. Severe protein restriction prevented progression of their acutely derived CKD.5 Severe protein restriction led to the animals’ demise, and severe protein
restriction in man would never again be contemplated,
akin to the protein-energy wasting incurred by some individuals with advanced CKD and ESRD.
It is important to note that in contradistinction to the
protein-hyperfiltration hypothesis, the group of Venkatachalam had posited that the presence of high protein was
not requisite to the acquisition of glomerulopathy; excessive caloric intake was.6 In his work, total caloric consumption provided the impetus for kidney injury, not
protein. This body of work adumbrated what has been reported in obese persons by Kambham, obesity-related
glomerulopathy (ORG), presumably the consequence of
glomerular hyperfiltration. It is important to note that
ORG appears less to follow a less pernicious course
than classical focal and segmental glomerulosclerosis.7
More recently, the Sirt1 gene (nicotinamide adenine
dinucleotide–dependent deacetylase sirtuin 1) has been
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implicated in the pathogenesis of obesity-induced proteinuria, during which time adiponectin levels are simultaneously depressed. Via Sirt1’s deacetylase activity,
downregulation of oxidative stress occurs through FoxO1
activation, which in turn raises adiponectin levels.8,9 In
obese African Americans, reduced adiponectin was
associated with albuminuria. In diabetic, adiponectin null
mice, podocyte effacement and proteinuria were present
with increases in oxidative stress via enhanced NADPH
oxidase Nox4 activity.10
As forewarned by Kambham, with obesity at epidemic
proportions—nearly one third of the United States is
obese, and 33 states have obesity rates greater than 25
percent—the ORG population will commensurately expand.11 This problem is not a national one; it is global.
Of the 1.4 billion overweight persons worldwide, in
2008, 1.5 billion persons were considered obese, and the
proportion of children less than 5 years old who were
overweight or obese was increasing. Per Hsu and colleagues, this weighty factor explains much of the reason
for the global epidemic of diabetes, which is strongly associated with proteinuria and ESRD.12
However, diabetes may only represent part of the end of
the chain initiated by the addition of high fructose corn
syrup-containing foods (5.2 tablespoons pure fructose
or 2.5 sugar-sweetened beverages daily), which may
foster elevated blood pressure and hyperuricemia.13,14
The pathogenesis of uric acid lithiasis, of which
hyperuricemia is not a requisite because fractional
excretions of urate are highly variable in diabetics, occurs
principally because of low urine ammonium and pH.
This pathogenetic sequence derives from obesity-related
insulin resistance, and the observation that uric acid
stone-formers ‘‘run in families’’ may be explicated by the
prevalence of obesity within families.15,16 The relatively
low urinary citrate and pH of insulin-resistant patients is
most effectively combated in this circumstance by ingestion
of a proportionally higher alkaline diet, namely one that is
more vegetarian in composition and ideally with a lesser
caloric intake, which could reduce insulin resistance
through weight loss. This strategy complements a diet of
enhanced intake of citrate-containing fluids and reduction
of animal protein ingestion and, hence, purine intake. In addition to its role in kidney stone formation, uric acid has
been linked to kidney disease onset and progression. Although it remains controversial if this link is causal, recent
clinical studies suggest that lowering uric acid levels might
delay the need for kidney replacement therapy.17 Notwithstanding their limitations, such studies suggest that dietary
modifications that lower serum uric acid levels could reduce incident CKD and retard its progression.
The reasons for the inability of kidney nutritional therapy to penetrate each practitioner’s medical armamentarium are painstakingly enumerated by a former mentor of
mine (A.G. Wasserstein, MD) as a series of responses to
a multitude of seemingly disparate forces.18 These

included personalities, philosophic orientations, economics, cultural dissimilarities, medical knowledge, the
evolution of medical practice, and the medical school
curriculum. Nevertheless, whether intact nephrons that
hyperfilter under the injurious load of excessive protein
represented the final common pathway toward glomerular and then nephronal obsolescence was to be
definitively determined by the multicenter trial, the
Modification of Diet in Renal Disease; it was not. The
study was marred at the outset by the protein-restricted
patients’ nonadherence with the prescribed dietary intervention. After all, the conduct of this randomized,
controlled trial occurred in the USA, one of the highest
protein-consuming countries worldwide.19 Thus, one
might conclude that the actual study has never been done.
Dr. Wasserstein abjured ‘‘paternalism’’ between interactions of nephrologists with kidney dietitians. To ignore
the kidney dietitian’s recommendations principally because of one’s own ignorance of adequate nutritional
training is wrong, and patients potentially lose the benefits of kidney nutritional therapy. Therefore, to prolong
the patient’s time before ESRD, seek and use the advice
of those unheralded caregivers, kidney nutritionists. In
fact, consider renewing your knowledge base and that of
those health-care workers with which you are involved
by reviewing the excellent, medical nutrition therapy materials available from the National Kidney Disease Education Program.20 Reducing calories, protein, sodium,
potassium, and phosphate harms neither the patient nor
the practitioner because inaction may inure more complications of CKD and/or its progression. It is time to move
forward from the past so that we may look back at our
future, which shall show that we have improved CKD
care through scientific and far-reaching nutritional
intervention(s).
Jerry Yee, MD
Editor-in-Chief
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